$AVEO and $DXTR,,,These are two stocks to watch in my opinion.
$AVEO,,,Closed Friday at $2.22 then had an increase of $.07 in After-Hour trading. The 5 day chart looks great with The MacD turning upward. The RSI (48.45) & Stochasitics (48.14 %k) in the 5 day chart looks good. Everything on the 1 day chart looks good however, slow Stochastics is high (82.70 %k) and is turning down for now. Although I realize I might miss some quick upward action at the bell, I will wait until later Monday to see what happens before deciding on a position or not.
$DXTR,,,Closed Friday @ $.30 then had a nice bump up of $.02 in After-Hours. Chart looks good to me. MacD turning up, RSI and Stochastics are under the 50% range and headed up. This week should look good. Take profits as they are given.
ARTICLE on BOTH:
Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) are making a strong comeback as they have jumped 328.86% since bottoming out at $0.5 on Mar. 28, 2017. Thanks to a rise of almost 194.04% in the past five days, the stock price is now up 296.3% so far on the year — still in strong territory. In this case, shares are down -11.57% from $2.42 , the 52-week high touched on Jun. 28, 2017, and are keeping their losses at 127.08% for the past 12 months.
Is It Worth the Risk?
Brokerage houses, on average, are recommending investors to buy AVEO Pharmaceuticals, Inc. (AVEO)’s shares projecting a $2.3 target price. What do this target means? Price targets reflect what the analyst believes a stock will be worth four quarters into the future. Are investors supposed to sell when the stock hits the target? Price targets frequently change, depending on the outlook for a company’s earnings. Sometimes it may seem like it, but analysts don’t just pull their price targets out of thin air. Typically, they estimate what the company’s earnings and cash flow will be for the next couple of years, and then apply a ratio – such as a price-to-earnings ratio – to those estimates to determine what the future stock price should theoretically be.
Revenue Growth Rates
AVEO’s revenue has declined at an average annualized rate of about -56.7% during the past five years. However, the company’s most recent quarter increase of 108.3% looks attractive.
Comparing Profitability
While there are a number of profitability ratios that measure a company’s ability to generate profit from the sales or services it provides, one of the most important is the net profit margin. It tells us what percentage of revenue a company keeps after all its bills are paid. While the higher this number is, the better, there is no gold standard. That’s why this number shouldn’t be looked at in isolation, but should be compared to a company’s peer group as well as its sector. Currently, AVEO Pharmaceuticals, Inc. net profit margin for the 12 months is at -728.85%. Comparatively, the peers have a net margin -529.49%, and the sector’s average is -7.78%. In that light, it seems in weak position compared to its peers and sector.
Dextera Surgical Inc. (NASDAQ
XTR) is another stock that is grabbing investors attention these days. Its shares have trimmed -90.03% since hitting a peak level of $2.9404 on Aug. 01, 2016. Thanks to an increase of almost 57.67% in the past one month, the stock price is now with underperforming -69.47% so far on the year — still in weak zone. In this case, shares are 72.41% higher from $0.17, the worst price in 52 weeks suffered on Jun. 08, 2017, but are collecting gains at -68.48% for the past six months.
Trading The Odds
The good news is there’s still room for the share price to grow. At recent closing price of $0.29, DXTR has a chance to add $1.81 or 624.14% in 52 weeks, based on mean target price ($2.1) placed by analysts.The analyst consensus opinion of 2 looks like a hold. It has a 36-month beta of -0.88 , so you might not be in for a bumpy ride.
EPS Growth Rates
For the past 5 years, Dextera Surgical Inc.’s EPS growth has been nearly -5.5%. Sure, the percentage is discouraging but better times are ahead as looking out over a next 5-year period, analysts expect the company to see its earnings go up by 25%, annually.
Is it turning profits into returns?
Two other important profitability ratios for investors to know are both returns-based ratios that measure a company’s ability to create wealth for shareholders. They are return on equity and return on assets. Return on equity measures is a company’s ability to turn an investor’s equity into profit. The higher the return on equity, the better job a company is at optimizing the investment made on shareholders’ behalf. Dextera Surgical Inc.’s ROE is 0%, while industry’s is 13.54%. The average ROE for the sector stands at -4.33%.
Return on assets, on the other hand, measures a company’s ability to turn assets such as cash, buildings, equipment, or inventory into more assets. DXTR’s ROA is -126.99%, while industry’s average is -653.52%. As with any return, the higher this number the better. However, it, too, needs to be taken into the context of a company’s peer group as well as its sector. The average return on assets for companies in the same sector is -10.87.
$AVEO,,,Closed Friday at $2.22 then had an increase of $.07 in After-Hour trading. The 5 day chart looks great with The MacD turning upward. The RSI (48.45) & Stochasitics (48.14 %k) in the 5 day chart looks good. Everything on the 1 day chart looks good however, slow Stochastics is high (82.70 %k) and is turning down for now. Although I realize I might miss some quick upward action at the bell, I will wait until later Monday to see what happens before deciding on a position or not.
$DXTR,,,Closed Friday @ $.30 then had a nice bump up of $.02 in After-Hours. Chart looks good to me. MacD turning up, RSI and Stochastics are under the 50% range and headed up. This week should look good. Take profits as they are given.
ARTICLE on BOTH:
Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) are making a strong comeback as they have jumped 328.86% since bottoming out at $0.5 on Mar. 28, 2017. Thanks to a rise of almost 194.04% in the past five days, the stock price is now up 296.3% so far on the year — still in strong territory. In this case, shares are down -11.57% from $2.42 , the 52-week high touched on Jun. 28, 2017, and are keeping their losses at 127.08% for the past 12 months.
Is It Worth the Risk?
Brokerage houses, on average, are recommending investors to buy AVEO Pharmaceuticals, Inc. (AVEO)’s shares projecting a $2.3 target price. What do this target means? Price targets reflect what the analyst believes a stock will be worth four quarters into the future. Are investors supposed to sell when the stock hits the target? Price targets frequently change, depending on the outlook for a company’s earnings. Sometimes it may seem like it, but analysts don’t just pull their price targets out of thin air. Typically, they estimate what the company’s earnings and cash flow will be for the next couple of years, and then apply a ratio – such as a price-to-earnings ratio – to those estimates to determine what the future stock price should theoretically be.
Revenue Growth Rates
AVEO’s revenue has declined at an average annualized rate of about -56.7% during the past five years. However, the company’s most recent quarter increase of 108.3% looks attractive.
Comparing Profitability
While there are a number of profitability ratios that measure a company’s ability to generate profit from the sales or services it provides, one of the most important is the net profit margin. It tells us what percentage of revenue a company keeps after all its bills are paid. While the higher this number is, the better, there is no gold standard. That’s why this number shouldn’t be looked at in isolation, but should be compared to a company’s peer group as well as its sector. Currently, AVEO Pharmaceuticals, Inc. net profit margin for the 12 months is at -728.85%. Comparatively, the peers have a net margin -529.49%, and the sector’s average is -7.78%. In that light, it seems in weak position compared to its peers and sector.
Dextera Surgical Inc. (NASDAQ
XTR) is another stock that is grabbing investors attention these days. Its shares have trimmed -90.03% since hitting a peak level of $2.9404 on Aug. 01, 2016. Thanks to an increase of almost 57.67% in the past one month, the stock price is now with underperforming -69.47% so far on the year — still in weak zone. In this case, shares are 72.41% higher from $0.17, the worst price in 52 weeks suffered on Jun. 08, 2017, but are collecting gains at -68.48% for the past six months. Trading The Odds
The good news is there’s still room for the share price to grow. At recent closing price of $0.29, DXTR has a chance to add $1.81 or 624.14% in 52 weeks, based on mean target price ($2.1) placed by analysts.The analyst consensus opinion of 2 looks like a hold. It has a 36-month beta of -0.88 , so you might not be in for a bumpy ride.
EPS Growth Rates
For the past 5 years, Dextera Surgical Inc.’s EPS growth has been nearly -5.5%. Sure, the percentage is discouraging but better times are ahead as looking out over a next 5-year period, analysts expect the company to see its earnings go up by 25%, annually.
Is it turning profits into returns?
Two other important profitability ratios for investors to know are both returns-based ratios that measure a company’s ability to create wealth for shareholders. They are return on equity and return on assets. Return on equity measures is a company’s ability to turn an investor’s equity into profit. The higher the return on equity, the better job a company is at optimizing the investment made on shareholders’ behalf. Dextera Surgical Inc.’s ROE is 0%, while industry’s is 13.54%. The average ROE for the sector stands at -4.33%.
Return on assets, on the other hand, measures a company’s ability to turn assets such as cash, buildings, equipment, or inventory into more assets. DXTR’s ROA is -126.99%, while industry’s average is -653.52%. As with any return, the higher this number the better. However, it, too, needs to be taken into the context of a company’s peer group as well as its sector. The average return on assets for companies in the same sector is -10.87.
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
